18F-fluoro-L-thymidine-PET for the evaluation of primary brain tumours in children: A report of three cases

Nuclear Medicine Communications

Volumn 31, Issue 6, 2010, Pages 482-487

  Gilles, Rozemarie ^a   Vogel, Wouter V ^a   Gidding, Corrie E M ^a   Janssens, Geert O R J ^a   Van Der Vliet, Ton M ^a   Oyen, Wim J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Fluoro L thymidine; Fluorodeoxyglucose; MRI; Paediatric brain tumours; PET

Indexed keywords

CLINDAMYCIN; DENDRITIC CELL VACCINE; DNA; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; TEMOZOLOMIDE; THYMIDINE;

ADOLESCENT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BIOPSY TECHNIQUE; CANCER RADIOTHERAPY; CASE REPORT; CHILD; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE DURATION; DNA SYNTHESIS; FEMALE; GLIOMA; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; INFECTION; MALE; MULTIPLE CYCLE TREATMENT; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRESCHOOL CHILD; PROGNOSIS; RECURRENT DISEASE; STEREOTACTIC BODY RADIATION THERAPY;

ADOLESCENT; BRAIN NEOPLASMS; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; DIDEOXYNUCLEOSIDES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INFANT; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY;

EID: 77951765512     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328318dc18     Document Type: Article

References (20)

1. Delbeke D, Martin WH. Metabolic imaging with FDG: a primer. Cancer J 2004; 10:201-213.
2. Oliviero WC, Dulebohn SC, Lister JR. The use of PET in evaluating patients with primary brain tumours: is it useful? J Neurol Neurosurg Psychiatry 1995; 58:250-252.
3. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn- Crews JM, et al. Imaging proliferation in vivo with [F-18] FLT and positron emission tomography. Nat Med 1998; 4:1334-1336.
4. Francis DL, Visvikis D, Costa DC, Arulampalam TH, Townsend C, Luthra SK, et al. Potential impact of [18F] 30-deoxy-30-fluorothymidine versus [18F] fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging 2003; 30:988-994.
5. Seitz U, Wagner M, Neumaier B, Wawra E, Glatting G, Leder G, et al. Evaluation of pyrimidine metabolizing enzymes and in vitro uptake of 30-[(18) F] fluoro-30-deoxythymidine ([(18) F] FLT) in pancreatic cancer cell lines. Eur J Nucl Med Mol Imaging 2002; 29:1174-1181.
6. Vesselle H, Grierson J, Muzi M, Pugsley JM, Schmidt RA, Rabinowitz P, et al. In vivo validation of 30deoxy-30-[(18) F] fluorothymidine ([(18) F] FLT) as a proliferation imaging tracer in humans: correlation of [(18) F] FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumours. Clin Cancer Res 2002; 8:3315-3323.
7. Van Westreenen HL, Cobben DC, Jager PL, van Dullemen HM,Wesseling J, Elsinga PH, et al. Comparison of 18F-FLT PET and 18F-FDG PET in oesophageal cancer. J Nucl Med 2005; 46:400-404.
8. Apisarnthanarax S, Alauddin MM, Mourtada F, Ariga H, Raju U, Mawlawi O, et al. Early detection of chemoradioresponse in oesophageal carcinoma by 30-deoxy-30-3H-fluorothymidine using preclinical tumour models. Clin Cancer Res 2006; 12:4590-4597.
9. Buck AK, Bommer M, Stilgenbauer S, Juweid M, Glatting G, Schirrmeister H, et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res 2006; 66:11055-11061.
10. Jacobs AH, Thomas A, Kracht LW, Li H, Dittmar C, Garlip G, et al. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumours. J Nucl Med 2005; 46: 1948-1958.
11. Choi SJ, Kim JS, Kim JH, Oh SJ, Lee JG, Kim CJ, et al. [18F]30-deoxy-30- fluorothymidine PET for the diagnosis and grading of brain tumours. Eur J Nucl Med Mol Imaging 2005; 32:653-659.
12. Van de Brande JL, Heymans HAS, Monnens LAH. Kindergeneeskunde. Maarssen: Elsevier/Bunge; 1998.
13. Stupp R, Janzer RC, Hegi ME, Villemure JG, Mirimanoff RO. Prognostic factors for low-grade gliomas. Semin Oncol 2003; 30 (6 Suppl 19):23-28.
14. Buckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol 2003; 30 (6 Suppl 19):10-14.
15. Ricci PE. Imaging of adult brain tumours. Neuroimaging Clin N Am 1999; 9:651-669.
16. Borgwardt L, Højgaard L, Carstensen H, Laursen H, Nowak M, Thomsen C, et al. Increased fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) uptake in childhood CNS tumours is correlated with malignancy grade: a study with FDG positron emission tomography/magnetic resonance imaging co registration and image fusion. J Clin Oncol 2005; 23:3030-3037.
17. Saga T, Kawashima H, Araki N, Takahashi JA, Nakashima Y, Higashi T, et al. Evaluation of primary brain tumours with FLT-PET: usefulness and limitations. Clin Nucl Med 2006; 31:774-780.
18. Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, et al. Imaging proliferation in brain tumours with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 2005; 46:945-952.
19. Muzi M, Spence AM, O'Sullivan F, Mankoff DA,Wells JM, Grierson JR, et al. Kinetic analysis of 30-deoxy-30-18F-fluorothymidine in patients with gliomas. J Nucl Med 2006; 47:1612-1621.
20. Troost EGC, Vogel WV, Merkx MAW, Slootweg PJ, Marres HAM, Peeters WJM, et al. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med 2007; 48:726-735.